Company Overview of Dermira, Inc.
Dermira, Inc., a specialty biopharmaceutical company, focuses on the development and commercialization of medical dermatology products to dermatologists and their patients primarily in the United States. The company’s late-stage product candidates comprise Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor, which is in Phase III clinical trial for the treatment of moderate-to-severe plaque psoriasis; DRM04, a small-molecule anticholinergic product that has completed a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01, a sebum inhibitor, which has completed a Phase IIa clinical trial for the treatment of acne. Its early-stage progra...
275 Middlefield Road
Menlo Park, CA 94025
Founded in 2010
Key Executives for Dermira, Inc.
Dermira, Inc. does not have any Key Executives recorded.
Dermira, Inc. Key Developments
Dermira, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Provides Earnings Guidance for the Year 2015
Mar 25 15
Dermira, Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, loss from operations was $6,782,000 against $6,692,000 last year. Net loss was $6,727,000 compared to $6,714,000 a year ago. Net loss per basic and diluted share was $0.29 against $7.56 last year. Revenue for the quarter ended December 31, 2014 was $7.3 million.
For the year ended, loss from operations was $31,698,000 against $22,303,000 last year. Net loss was $31,875,000 compared to net loss of $22,350,000 last year. Net loss per basic and diluted share was $4.96 against $27.03 last year. Revenue for the year ended December 31, 2014 was $7.3 million.
For the year 2015, the company expects non-GAAP operating expenses for 2015, excluding the impact of stock-based compensation expense, to be in the range of $80 million to $85 million and to have approximately $90 million in cash and cash equivalents and investments as of year-end 2015.
Dermira, Inc. Presents Clinical Data from Its Successful DRM01 Phase 2a Trial in Patients with Facial Acne Vulgaris
Mar 23 15
Dermira, Inc. announced the presentation of clinical data from its successful DRM01 Phase 2a trial in patients with facial acne vulgaris. The primary endpoints in this trial, the changes from baseline in inflammatory and non-inflammatory lesion counts and an improvement in the Investigator's Global Assessment (IGA) of acne, were met with statistical significance. DRM01 was generally well tolerated with no reported serious treatment-related adverse events. These results were presented during the Late-Breaking Research in Dermatology Forums at the American Academy of Dermatology (AAD) Annual Meeting on March 20, 2015 in San Francisco. This was the first presentation of DRM01 data at a medical meeting. DRM01 Phase 2a Trial Design and Results: This Phase 2a clinical trial was a randomized, multi-center, double-blind, vehicle-controlled study that enrolled 108 patients with moderate or severe acne. Inclusion criteria required a minimum of 20 inflammatory lesions and 20 non-inflammatory lesions and an IGA score of three or greater on a five-point scale that ranges from a score of zero, representing clear skin, to a score of four, representing severe disease. Patients were instructed to apply either DRM01 at a concentration of 7.5% or vehicle to the face twice daily for 12 weeks. A total of 53 subjects were randomized to receive DRM01, and the other 55 were randomized to receive vehicle only. The primary efficacy endpoints used in this trial consisted of absolute changes from baseline to week 12 in the numbers of inflammatory and non-inflammatory lesions and the proportion of patients with at least a two-grade improvement from baseline to week 12 in IGA score. DRM01 demonstrated statistically significant improvements from baseline to week 12 relative to vehicle in all primary efficacy endpoints. The number of inflammatory lesions in patients treated with DRM01 was reduced by an average of 19.3 compared to 13.3 in patients who received the vehicle only (p=0.0003), or an average percentage reduction of 63.9% and 45.9%, respectively (p=0.0006). The number of non-inflammatory lesions in patients treated with DRM01 was reduced by an average of 19.9 compared to 11.2 in patients who received the vehicle only (p=0.0032), or an average percentage reduction of 48.1% and 28.8%, respectively (p=0.0025). At the end of the 12-week treatment period, 24.5% of patients (13/53) who received DRM01 achieved a successful improvement in the IGA score (minimum two-grade improvement), in comparison with 7.3% of patients (4/55) who received the vehicle only (p=0.0070). DRM01 was well-tolerated with adverse events mild or moderate in severity. The most frequently reported adverse event was nasopharyngitis, which was reported in 13 (24.5%) of the patients treated with DRM01 and in 7 (12.7%) of the patients who received vehicle and which was considered unrelated to treatment. Application-site conditions, which are frequently observed in most clinical trials of topical products, also were observed. No treatment-related serious adverse events were reported.
Dermira, Inc. to Report Q4, 2014 Results on Mar 25, 2015
Mar 18 15
Dermira, Inc. announced that they will report Q4, 2014 results at 5:00 PM, Eastern Standard Time on Mar 25, 2015
Similar Private Companies By Industry
Recent Private Companies Transactions
September 19, 2014
August 15, 2014
July 3, 2014